CompletedPhase 2NCT01086540
Rituximab for Treatment of Systemic Sclerosis-Associated Pulmonary Arterial Hypertension (SSc-PAH)
Studying Systemic sclerosis
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- Principal Investigator
- Mark Nicolls, M.D.Stanford University
- Intervention
- Rituximab(biological)
- Enrollment
- 57 enrolled
- Eligibility
- 18-75 years · All sexes
- Timeline
- 2011 – 2019
Study locations (17)
- Stanford Health Care, Stanford, California, United States
- University of Colorado Health Sciences Center, Aurora, Colorado, United States
- University of Iowa, Iowa City, Iowa, United States
- Johns Hopkins University, Pulmonary and Critical Care Medicine, Baltimore, Maryland, United States
- Boston University Medical Center, Boston, Massachusetts, United States
- University of Michigan, Ann Arbor, Michigan, United States
- University of Minnesota Health Clinics and Surgery Center, Minneapolis, Minnesota, United States
- Columbia University Medical Center, New York, New York, United States
- Weill Cornell Medical College, New York, New York, United States
- University of Rochester Medical Center, Rochester, New York, United States
- University of North Carolina at Chapel Hill: UNC Hospitals, Chapel Hill, North Carolina, United States
- Ohio State University, Columbus, Ohio, United States
- University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States
- Medical University of South Carolina, Charleston, South Carolina, United States
- University of Texas Southwestern Medical Center-William P. Clements University Hospital, Dallas, Texas, United States
- +2 more locations on ClinicalTrials.gov
Collaborators
Autoimmunity Centers of Excellence · Rho Federal Systems Division, Inc.
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT01086540 on ClinicalTrials.govOther trials for Systemic sclerosis
Additional recruiting or active studies for the same condition.
- RECRUITINGNANCT07402226Systemic Sclerosis DIet for GastrointESTinal SymptomsUniversity of Michigan
- RECRUITINGEARLY PHASE1NCT07355972Safety, Efficacy and Cellular Metabolic Dynamics of CT1195E in Patients With Refractory / Progressive SSCUnion Hospital, Tongji Medical College, Huazhong University of Science and Technology
- RECRUITINGNANCT07360808Safety and Efficacy of Adipose-Derived Regenerative Cells (ADRCs) for Improving Hand Dysfunction in Systemic SclerosisCytori Therapeutics
- RECRUITINGNCT07228429Quantification of Calcinosis Cutis Disease Burden Using Computed Tomography ImagesYale University
- RECRUITINGPHASE1NCT07167537A Study of OL-CD19-GDT in Relapsed/ Refractory Autoimmune DiseasesBeijing GoBroad Hospital
- RECRUITINGEARLY PHASE1NCT07000682The Clinical Study on the Treatment of SSc With UTAA91 Injection.Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
- RECRUITINGNCT06865118Home-Based Clinical Management of Cardiac Complications in Systemic SclerosisOslo University Hospital
- RECRUITINGNANCT06675344The Apollo Device in Systemic Sclerosis for the Management of fatiguE, Raynaud Phenomenon and qualiTy of LifeRobyn T. Domsic, MD, MPH